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Abstract
SUMO is a novel ubiquitin-like protein that can cova-
lently modify a large number of nuclear proteins. SUMO
modification has emerged as an important regu-
latory mechanism for protein function and localization.
Sumoylation is a dynamic process that is mediated by
activating (E1), conjugating (E2), and ligating (E3)
enzymes and is readily reversed by a family of SUMO-
specific proteases (SENPs). Since SUMO was dis-
covered 10 years ago, the biologic contribution of this
posttranslational modification has remained unclear. In
this review, we report that SENP1, a member of the
SENP family, is overexpressed in human prostate
cancer specimens. The induction of SENP1 is observed
with the chronic exposure of prostate cancer cells to
androgen and/or interleukin (IL) 6. SENP1 upregulation
modulates the transcriptional activity of androgen
receptors (ARs) and c-Jun, as well as cyclin D1 ex-
pression. Initial in vivo data from transgenic mice
indicate that overexpression of SENP1 in the prostate
leads to the development of prostatic intraepithelial
neoplasia at an early age. Collectively, these studies
indicate that overexpression of SENP1 is associated
with prostate cancer development.
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The Sumoylation Pathway
In late 1996 until early 1997, our laboratory and several
others reported a novel ubiquitin-like protein called sentrin-1
(or SUMO1, GMP1, PIC1, SMT3, and UBL1) [1–5]. In the
ensuing years, the acronym SUMO (small ubiquitin-like
modifier) gained wide acceptance and, thus, will be used
throughout this review. However, it should be noted that
sentrin was used in our early publications.
There are three SUMO family members, which slightly
vary in length. SUMO1 is a 101–amino acid protein, SUMO2
is a 103–amino acid protein, and SUMO3 is a 95–amino
acid protein [6]. SUMO2 and SUMO3 are more closely
related to each other (93.6% identity in 94-residue overlap)
compared with SUMO1 (52.4% identity in 84-residue
overlap). SUMO homologues have been reported from
Arabidopsis thaliana to Homo sapiens, suggesting that
SUMO is an evolutionarily conserved protein that may have
unique functions in cellular metabolism.
There is a remarkable conservation of the mechanisms
between ubiquitination and sumoylation pathways. However,
the activating (E1), conjugating (E2), and ligating (E3) enzymes
involved in sumoylation are entirely distinct from ubiquitin E1,
E2, and E3.
The E1 for SUMO is composed of two subunits, Aos1 and
Uba2 [7,8]. Aos1 is homologous to the N-terminal half of
Uba1, the yeast-activating enzyme (E1) for ubiquitin [9],
whereas Uba2 is similar to the C-terminal half Uba1 (Figure 1).
Formation of the Uba2–SUMO thiol ester adduct is an ATP-
dependent process that is similar to the mechanism of action
of the ubiquitin-activating enzyme (E1). Our laboratory has
discovered a specific SUMO-conjugating enzyme (Ubc9) in a
yeast two-hybrid screen using SUMO1 as bait [10]. Ubc9 was
able to form a thiol ester adduct with SUMO1, but not with
ubiquitin. Thus, in contrast to the large number of E2s used in
the ubiquitination pathway, Ubc9 is the only known conjugating
enzyme for the sumoylation pathway [10,11].
More recently, three types of SUMO E3s have been dis-
covered. The first type is composed of the PIAS (protein in-
hibitor of the activator of STAT) family of proteins [12,13]. The
second type is RanBP2, which is localized in the nuclear pore
complex [14]. The third type is Pc2, which is a component of
polycomb protein complexes [15]. RanGAP1 and PML are
the first two sumoylated substrates to have been identified
[2,3,16]. However, the list of sumoylated proteins has expanded
significantly in the last few years to include p53, MDM2, top-
oisomerase I, topoisomerase II, androgen receptor (AR), SRC1,
GRIP1, p300, and histone deacetylase (HDAC) 1 [17–25]
(Figure 2). In contrast to ubiquitination, sumoylation does not
target proteins for degradation. Sumoylation, in some cases,
actually competes with ubiquitination on the same lysine resi-
dues, thus functioning almost like an antiubiquitin [26]. Sumo-
ylation can also alter a protein’s cellular localization. For example,
sumoylated RanGAP1 is localized in the nuclear envelope,
whereas unmodified RanGAP1 is localized in the cytosol [2,3].
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Finally, sumoylation of many transcriptional factors serves
to alter their transcriptional activity [17,18,24,27–33].
Reversal of Sumoylation by SUMO-Specific
Proteases (SENPs)
Sumoylation is a dynamic process that is readily reversed
by a family of SENPs [34] (Figure 3). In the mammalian sys-
tem, six SENPs have been reported [34–40] (Figure 4).
SENP1 is a nuclear protease that deconjugates a large
number of sumoylated proteins [40] (Figure 5). SENP2 is a
nuclear envelope–associated protease that, when over-
expressed, appears to have an activity similar to that of
SENP1 [36,40–42] (Figure 5). There is a spliced isoform of
mouse SENP2, called SuPr1, which could alter the distribu-
tion of nuclear POD-associated proteins, such as CBP and
Figure 1. The SUMO modification pathway. On the first step of the process, the C-terminus reveals the Gly–Gly (G–G) residues for conjugation. Aos1 and Uba2
constitute the activating enzyme complex (E1). Ubc9 is the only known SUMO-conjugating enzyme (E2). E3 denotes SUMO ligases.
Figure 2. SUMO-modified proteins. A partial list of SUMO-modified proteins is presented.
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Daxx, and could convert Sp3 to a strong activator with dif-
fuse nuclear localization [31,35]. We have recently reported
SENP3 and SENP5 to constitute a family of nucleolar SENPs
with preference for SUMO2/3 [43]. The third SENP family
consists of SENP6 and SENP7—two nuclear proteases with
unknown function. Although the ability of SENPs to reverse
sumoylation is well established, the specificity of each
SENP and the overall biologic relevance of the SENP family
remain undefined.
Sumoylation of ARs, c-Jun, and Coregulatory Proteins
Numerous cellular targets of SUMO targets modulate tran-
scription. Steroid receptors such as ARs, which are ligand-
regulated transcription factors belonging to the nuclear
receptor superfamily [44], have been reported as SUMO-
ylated proteins. ARs are sumoylated in vivo at lysine residues
386 and 520 [21]. Mutation of these residues increases the
transactivation ability of ARs, suggesting that sumoylation
is involved in the repression of AR activity [21].
c-Jun is a transcription factor that plays an important role in
regulating cell growth, apoptosis, differentiation, and transfor-
mation. The transcriptional activity of c-Jun can be regulated
by both phosphorylation and sumoylation. c-Jun is conjugated
by SUMO at amino acids 229 and 257, with sumoylation
negatively regulating c-Jun–dependent transcription [33,45].
It is well known that both ARs and c-Jun interact with
various coregulatory proteins; this interaction can regulate
the transcriptional activity of nuclear receptors and tran-
scription factors.
Recently, it has been found that four AR coregulators are
sumoylated. These AR coregulatory proteins either trans-
activate or transrepress AR transcriptional activity by binding
the specific functional domains of receptors (the N-terminal
transactivation region, the central DNA-binding domain, and
the C-terminal ligand-binding domain). The transactivator
SRC1, for example, has five sumoylation sites, and two major
sites are localized in a nuclear receptor box situated in the
nuclear receptor–interacting region 1 [22]. It was observed
that sumoylation could increase the interaction of SRC1 with
progesterone receptors. For the coactivator GRIP1, two resi-
dues located in the nuclear receptor–interacting region were
found to be sumoylated [46]. Substitution of these two sumo-
ylation sites could attenuate the activity of GRIP1 on AR-
dependent transcription. The transrepressors HDAC1 and
HDAC4werealso found tobe sumoylated [25,47,48].Mutation
of the two sumoylation sites of HDAC1 profoundly reduced
HDAC1-mediated transcriptional repression [25]. An HDAC4
sumoylation mutant showed a slightly impaired ability to
repress transcription, as well as reduced HDAC activity [28].
Similarly, p300 is a well-known coactivator of c-Jun
[49–52] that has been shown to physically interact with
c-Junand to activate c-Jun–dependent transcription [50]. Be-
cause the transcriptional activity of p300 can bemodulated by
a number of signaling pathways, p300 provides an additional
level of regulation for c-Jun–dependent transcription.
It has been reported that p21 regulates p300 transcrip-
tional activity [53–55]. p21 not only inhibits p300-bound
cyclin E-Cdk2 activity through repression of the histone
acetyltransferase activity of p300 [56] but also stimulates
p300 transactivation [55]. Within p300, a domain named
CRD1 has been identified as a domain with strong transcrip-
tional repression [55]. CRD1 functions independently of p300
histone acetyltransferase domains, but can repress the trans-
activational activity of p300 [55]. p21 derepresses this CRD1
activity and, thus, selectively activates p300-dependent
transcription at specific promoters. Recent findings indicate
that sumoylation is required for CRD1-dependent transcrip-
tional repression [24]. The two SUMO modification sites
within the CRD1 domain of p300 have been identified, and
mutation at these two sites can reduce the repression of
CRD1 domain and p21 inducibility [24]. Therefore, SUMO
modification provides a new mechanism to control p300
Figure 3. Sumoylation is a dynamic and reversible process. E1, SUMO-
activating enzyme; E2, SUMO-conjugating enzyme; E3, SUMO ligase.
Figure 4. The human SENP family. Six SENPs share a conserved catalytic domain with four highly conserved amino acids (H, D, Q, and C) and are grouped into
three families.
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function and potentially novel mechanisms for the regulation
of c-Jun–dependent transcriptional activities.
As ARs, c-Jun, and coregulatory proteins are sumoylated,
we believe that SENPswill play an important role in regulating
AR and c-Jun activity through the deconjugation of sumo-
ylated coregulators (see below).
SENP1 Regulates AR-Dependent Transcription
ARs and their coregulators provide us a good model with
which to determine the role of the desumoylation activity of
SENPs (Figure 6). We performed the initial survey by using
luciferase reporter gene assay to examine whether any of the
six SENPs could affect AR-dependent transcription. As
shown in Figure 7, SENP1 dramatically enhanced AR tran-
scriptional activity in LNCaP cells by 23-fold. This effect is
dependent on the presence of the AR ligand, R1881.
SENP1’s catalytic activity is required for this effect, as the
catalytically inactive mutant of SENP1 (R630L and K631M)
has no effect on AR-dependent transcription. Furthermore,
none of the other SENPs exerts any significant effect on
AR-dependent transcription. Similarly, SUMO1, SUMO2, or
Ubc9 overexpression also failed to enhance AR-dependent
transcription, suggesting that these components of SUMO
modification system are sufficient in cells. Thus, the effect of
SENP1 on AR-dependent transcription is unique among all
of the conjugation and deconjugation machinery of the
sumoylation pathway.
More interestingly, the mutation of two sumoylation sites
on ARs did not abolish SENP1 action, suggesting that the
SENP1 effect on AR-dependent transcription is not mediated
by AR sumoylation [57]. We then tested the role of the
sumoylation of SRC1, p300, and HDAC1 and showed that
the main target of SENP1 is HDAC1 in the SENP1-mediated
Figure 5. The subcellular localizations of SENPs. Overexpression images are presented.
Figure 6. ARs and the coregulators SRC1, p300, and HDAC1 are modified
by SUMO.
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enhancement of AR-dependent transcription [57]. Sumo-
ylation of HDAC1 is required for its transcription suppression.
An HDAC1 mutant that cannot be sumoylated has lost its
deacetylase activity (as demonstrated by deacetylase assay)
and, subsequently, its suppressive activity [57]. Thus, in
summary, when SENP1 is not present, AR-dependent tran-
scription occurs at low levels due mainly to the suppressive
effect of HDAC1. However, when SENP1 is present, HDAC1
is desumoylated and, therefore, loses its deacetylase activity
and ability to suppress transcription. Thus, AR-dependent
transcription would occur at high levels.
SENP1 Enhances c-Jun–Dependent Transcription
It has also been shown that c-Jun transcription can be
regulated by SuPr1, an alternative spliced form of SENP2.
However, SuPr1’s ability to enhance c-Jun transcription is
dependent on PML, but is independent of SuPr1’s desumo-
ylation activity. We showed that SENP1 also markedly en-
hances c-Jun’s transcription activity (Figure 8). The action of
SENP1 on c-Jun transcription is independent of the sumo-
ylation and phosphorylation status of c-Jun, but is critically
dependent on SENP1’s desumoylation activity [58]. We
further showed that p300 is essential for SENP1 to enhance
c-Jun–dependent transcription because SENP1 could de-
sumoylate the CRD1 domain of p300, thereby releasing the
cis repression of CRD1 on p300 [58]. The ability of SENP1 to
regulate c-Jun–dependent transcription may also play a role
in its involvement in tumorigenesis.
SENP1 Is Overexpressed in Prostatic Intraepithelial
Neoplasia (PIN) and Prostate Cancer
SENP1, acting as a strong activator for AR and c-Jun trans-
activation, prompted us to explore the potential role of
SENP1 in prostate cancer development. Prostate cancer is
the most frequently diagnosed cancer among the male
population in the United States [59]. Tumor formation in
prostate tissues accounts for 30% of cancer-related deaths
in men. In most cases, the disease progresses from benign
hyperplasia to a prostate cancer precursor state referred to
as PIN (Figure 9). PIN formation is replaced with rapidly
proliferating prostate cancer cells that readily metastasize
to other areas of the body. This atrophy of the prostate gland
is attributed to changes at the molecular level, specifically
with alterations in the expression and transcriptional ac-
tivity of numerous factors. The correlation between enhanced
AR-dependent transcriptional activity and prostate carcino-
genesis is accepted; in fact, the expression of the AR-
regulated prostate-specific antigen (PSA) gene is used as a
biologic marker for the diagnosis of prostate cancer [60,61].
The oncogenic property of c-Jun is well established. Recent
studies suggest a correlation between c-Jun levels and
prostate carcinogenesis; the expression of c-Jun is enhanced
with the progression of the carcinoma [62]. Because SENP1
overexpression directly regulates these two factors, we eval-
uated whether expression of SENP1 is observed in human
prostate cancer specimens. We first investigated the expres-
sion of SENP1 in normal prostate, PIN [63], and prostate
cancer using in situ hybridization technique. Nonradioactive
in situ hybridization was performed on 43 prostatectomy
cases with areas of both high-grade PIN and cancer. SENP1
messenger RNA was increased in 29 of 43 cases of high-
grade PIN (67%) (Figure 10A). Similarly, SENP1 expression
was increased in 26 of 43 prostate cancer samples (60%)
(Figure 10B). Thus, SENP1 expression is preferentially in-
creased during the development of prostate cancer in the
majority of cases.
SENP1 Induces Cyclin D1 Expression and Cell
Proliferation
Because overexpression of SENP1 modulates AR- and c-
Jun–dependent transcriptional activity and both factors are
Figure 8. SENP1 induces c-Jun–dependent transcription. PC-3 cells were
transfected with Gal4– luc and Gal4–DBD or Gal4–c-Jun plasmid in the
absence or presence of increasing amounts of SENP1 wild-type or mutant
plasmids. Luciferase activity was measured, and transfection efficiency was
normalized by -galactosidase expression.
Figure 7. SENP1 markedly enhances AR-dependent transcription. LNCaP
cells cotransfected luciferase with plasmids, as indicated in the figure. After
12 hours of transfection, cells were treated with 10 nm of R1881 for 24 hours,
and luciferase activity was measured. Transfection efficiency was normalized
using a -galactosidase expression construct, and the results are presented
as fold activation over an empty vector.
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known to mediate cell proliferation, we reasoned that over-
expression of SENP1 could regulate the proliferation of
prostate cancer cells. Indeed, when endogenous of SENP1
was silenced by SENP1 siRNA in LNCaP cells, growth was
significantly decreased. Provided SENP1 can strongly in-
crease AR transcriptional activity, it is of no doubt that the
effect of SENP1 on proliferation could be attributed to its
regulation for AR transcription. However, we observed similar
results in PC-3, an androgen-independent prostate cancer
cell line, suggesting that SENP1 could play a role in regu-
lating cell proliferation through pathways other than the
AR-dependent pathway. We also found that the number of
SENP1-silenced PC-3 cells in the G1 phase was significantly
increased but decreased in the S and G2/M phases, sug-
gesting that SENP1 plays a role in G1–S phase transition in
PC-3 cells. This slowing of the proliferation of SENP1-
silenced PC-3 cells may thus be due to an alteration in
G1–S phase progression.
There are numerous cell cycle regulators that control cell
proliferation and cell cycle progression [64,65]. Among them,
cyclins D1 and E are predominantly associated with cell
growth regulation and G1–S phase transition [66–68]. We
therefore reasoned that SENP1 might modulate cell prolifer-
ation and cell cycle progression by regulating the expression
of cyclins D1 and E. Silencing SENP1 expression decreased
the expression of cyclin D1, but not cyclin E, in PC-3 cells.
Conversely, stably transfected SENP1 in LNCaP cells en-
hanced cyclin D1 expression and cell proliferation. Interest-
ingly, cell proliferation is dependent on cyclin D1 expression
induced by SENP1 (Figure 11). Thus, the regulation of cyclin
D1 expression by SENP1 is another means through which
prostate cancer cell growth is regulated.
Wealso found that the induction of cyclin D1 expression by
SENP1 depended on its catalytic activity, as the mutation of
SENP1 catalytic domain disrupted its activity on cyclin D1
transcription and cell proliferation.We further determined that
HDAC1 is also the mediator for the SENP1 regulating cyclin
D1 expression.
Androgen and Interleukin (IL) 6 Induce SENP1
Transcription in Prostate Cancer Cells
The expression of SENP1 correlated with the manifestation
of prostate tumorigenesis and cell proliferation, but the
mechanism for SENP1 induction remained undefined. We
hypothesized that activation of ARs by their native agonist,
androgen, would upregulate SENP1 levels because the
biologic function of ARs is to directly modulate gene/protein
expression. To test this hypothesis, the human androgen–
sensitive cell line, LNCaP, was used. LNCaP cells were
exposed to the synthetic androgen, R1881 (20 nM), for 24
and 48 hours, and SENP1 mRNA levels were evaluated
using quantitative real-time polymerase chain reaction
(PCR). SENP1 expression is enhanced five-fold and seven-
fold with 24- and 48-hour R1881 treatment, respectively
(Figure 12A). Hence, continuous exposure to androgen in-
duces SENP1 expression.
Various cytokines are expressed in prostate cancer cells,
including IL-1, IL-6, and tumor necrosis factor a (TNF-a)
[69,70]; elevated serum levels of IL-6 and TNF-a have been
reported in patients with prostate cancer [61,71]. Unlike IL-1
and TNF-a, IL-6 promotes the activation of AR-dependent
transcription through the initiation of the MAPK and JAK/STAT
pathways [72–74]. To determine if androgen-independent
activation of ARs promotes SENP1 upregulation, LNCaP cells
were treated with 25 ng/ml IL-6, IL-1, or TNF-a for either 24 or
48 hours. SENP1 levels were enhanced in cells treated with
IL-6, but not with IL-1 or TNF (Figure 12B).
Figure 9. Pathogenesis of prostate cancer (reproduced with permission from the New England Journal of Medicine [59]).
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The relapse of prostate cancer occurs due to the adaptation
of ARs to low levels of androgen and activation by alternate
pathways [75,76]. To evaluate whether the combination of
androgen-dependent and androgen-independent pathways
on AR activation could regulate SENP1 expression, SENP1
levels were assessed following the treatment of LNCaP cells
with R1881 (20 nM), IL-6 (25 ng/ml), or both for 24 hours.
Treatment with either androgen or IL-6 produced approxi-
mately a five-fold increase in SENP1 levels (Figure 11). The
combination of both R1881 and IL-6 profoundly enhanced
SENP1 expression by more than seven-fold compared to
either compound alone (Figure 12C).
To ensure that the concentrations of R1881 and IL-6
were sufficient to activate AR-dependent transcription, the
expression of the AR-dependent protein PSA was evaluated.
Serum PSA levels are commonly used as diagnostic tools
for prostate cancer; PSA levels above 2.5 ng/ml indicate high
AR activity. The addition of R1881 (20 nM) or IL-6 (25 ng/ml)
for 24 hours significantly increased PSA protein levels com-
pared to controls (a 5.6-fold and a 2.2-fold increase in PSA
Figure 11. SENP1 regulates cyclin D1 expression in prostate cancer cells. SENP1 regulates cyclin D1 expression. (A) PC-3 cells were transfected with nonspecific
siRNA or SENP1 siRNA. (B) LNCaP cells were stably transfected with an empty vector, SENP1, or SENP1 mutant. Cyclin D1 protein levels were determined in
these cell clones.
Figure 10. Overexpression of SENP1 in prostate cancer tissues. (A–C) In situ hybridization showed that SENP1 was overexpressed in high-grade PIN (black
arrow; A) and cancer cells (black arrow; B and C), but not in normal epithelial cells (white arrow) in prostate cancer specimens. The insert in (C) was a sense probe
control. (D) Immunohistochemical staining of ARs in normal prostate glands (white arrowhead) and prostate cancer (black arrowhead).
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levels compared to controls, respectively) (Figure 12D). The
combination of R1881 and IL-6 further enhanced the pro-
duction of PSA (Figure 12D) with an 11-fold increase com-
pared to controls. Therefore, the addition of R1881 and/or
IL-6 enhances the transcriptional activity of AR as well as
SENP1 levels. We have demonstrated that inhibition of
SENP1 expression by siRNA reduces androgen-induced
PSA production in LNCaP cells [57]. Thus, it is likely that
SENP1 induction is essential for androgen and IL-6 to induce
PSA secretion.
PIN-Like Lesion Observed in the Prostate of SENP1
Transgenic Mice as Early as 4 Months of Age
We showed that IL-6 and androgen induce SENP1 ex-
pression in prostate cancer cells. SENP1 enhances c-
Jun–dependent transcription; SENP1 markedly increases
AR-dependent transcription, which leads to increase in PSA
secretion; SENP1 also increases cyclin D1 expression, lead-
ing to increase in cellular proliferation. Furthermore, SENP1
is highly expressed in PIN and prostate cancer, but not in
normal prostate tissues. Taken together, we hypothesize that
SENP1 has a great potential to initiate and promote the
development of prostate cancer.
We have generated a probasin-driven murine SENP1
transgenic mouse to determine the role of SENP1 in prostate
cancer development. Four transgenic mice lines with the
probasin-driven SENP1 transgene were identified using spe-
cific PCR primers. At 16 weeks, histologic studies on hema-
toxylin/eosin–stained prostate tissue specimens of two male
transgenic mice were performed. Compared to age-matched
wild-type mice (Figure 13A), preliminary data show the
Figure 12. The combination of androgen and IL-6 synergistically enhances SENP1 and PSA expression. SENP1 expression was examined in LNCaP cells treated
with R1881 (A); IL-4, IL-6, or TNF-a (B); or a combination of R1881 and IL-6 (C) for either 24 or 48 hours by real-time PCR. PSA expression was also examined in
LNCaP cells treated with R1881, IL-6, or R1881 + IL-6 by enzyme-linked immunosorbent assay (D).
Figure 13. Dysplasia in the prostate of SENP1 transgenic mice. The dorsolateral and ventral lobes of the prostate from either age-matched wild-type mice (A) or
16-week-old SENP1 transgenic mice (B) were stained with hematoxylin/eosin. Abnormal growth was observed in the dorsolateral prostate of transgenic mice
(highlighted with black arrow).
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development of PIN-like lesions in the dorsolateral lobe of
male SENP1 transgenic mice (Figure 13B). Studies in the
four established lines are currently underway to confirm that
SENP1 expression in transgenic mice prompts the develop-
ment of cancerous lesions in the prostate gland.
Conclusion
SENP1 is overexpressed in PIN and prostate cancer tissues,
but not in normal prostate tissues. The increase in SENP1
expression in PIN and prostate cancer is most likely in-
duced by androgen and IL-6. Induction of SENP1 will en-
hance AR-dependent transcription, c-Jun–dependent
transcription, and expression of cyclin D1, leading to increase
in cellular proliferation. Transgenic mice overexpressing
SENP1 in the prostate gland also showed evidence of early
PIN formation. Thus, SENP1 is likely to play a significant role
in the development of prostate cancer (Figure 14). This is the
first demonstration of the involvement of desumoylation in
cancer development.
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